Denise Neves Gameiro, Author at Labiotech.eu - Page 17 of 24

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

novozymes lactase saphera lactose free yogurt

News and Trends 20 Apr 2016

What’s the deal with Lactose free yogurt in Denmark?

Novozymes, the European leader for Industrial Biotech, has had a good start to 2016. It has now launched some new ideas, including for lactose-free food products. Novozymes is a giant in the production of enzymes, an important player in the ‘traditional Biotech’ biocatalysis revolution and a cornerstone in the Danish Biotech scene. The company has now released its financial […]

April 20, 2016 - 3 minutesmins - By Denise Neves Gameiro

nicox ac 170 cetirizine eye drop allergic

News and Trends 20 Apr 2016

French Biotech submits new Drug for Eye Allergies to the FDA

Nicox is filing a New Drug Application for its allergic conjuntivitis candidate, a novel eye drop formulation of a well-known antihistamine. Based in Sophia Antipolis (near the French Riviera), Nicox is developing therapies in ophthalmology. Now, it has submitted one of its candidates (AC-170) for FDA approval, after good results from two phase III trials evaluating both the safety and […]

April 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

stevenage biosciences catalyst catapult appolo MRC biotech

News and Trends 19 Apr 2016

Drug Discovery moves to Stevenage – the new Golden Triangle hotspot?

MRC Technology, a UK medical research charity, has moved most of its labs to the Stevenage Bioscience Catalyst (SBC) campus. Located inside the gold triangle, is this the new hotspot of UK Biotech? MRC Technology provides drug discovery services, as well as advice for commercialisation and intellectual property management, for academia and industry. Since it was founded […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

enterome vertex ibd bowel crohns

News and Trends 19 Apr 2016

French Microbiome Therapy boosted by compound from major US Biotech

Enterome, a leader in the European microbiome field, has struck a deal with US’ Vertex to develop novel small molecules with potential to treat inflammatory bowel diseases. With an impressive roll of partnerships and backed by the world-first Microbiome fund, Enterome is very well-positioned in hype field of the Microbiome. We discussed Enterome’s differentiated strategy […]

April 19, 2016 - 3 minutesmins - By Denise Neves Gameiro

gsk morphosys hand osteoarthritis rheumatoid

News and Trends 19 Apr 2016

GSK goes to phase II with German Antibody for Inflammatory Diseases

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165. The trial will enroll 40 patients with hand osteoarthritis – a condition that damages […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

oxford biotherapeutics drug cancer boehringer

News and Trends 18 Apr 2016

UK Drug Discovery sells Cancer Target to German Pharma

Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database. Oxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell. […]

April 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

ariad brigotinib nsclc lung cancer

News and Trends 18 Apr 2016

Very promising Results for Resistant Lung Cancer

Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival. Ariad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland). One of the hard-to-treat cancers that Ariad is targeting is […]

April 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

bioart thomas feuerstein bioreactors sculptures

News and Trends 17 Apr 2016

BioArt : Feeding the Mind with Thomas Feuerstein’s Living Machines and Green Organs

Thomas Feuerstein is an Austrian BioArtist who sculptures with living organisms and Biotechnology lab equipment – which challenges the mentality of hardcore Green science. Based in Innsbruck, Thomas originally studied Art History and Philosophy. His works started dwelling on Biotech during the 90’s, from when he was part of the Bibliophy project, which ran from 1995 to 2002. This aimed to discuss ideas […]

April 17, 2016 - 4 minutesmins - By Denise Neves Gameiro

nsclc mirati qiagen cancer oncology lung mrna

News and Trends 15 Apr 2016

Qiagen Deal to make Genetic Diagnostic Test for Lung Cancer

Qiagen and Mirati will collaborate on the development of a companion diagnostic for a specific type of form of Non-Small Lung Cancer – supporting Mirati’s new therapy. With its operational headquarters near Düsseldorf (Germany), Qiagen is an EU giant in Molecular Diagnostics, and even stepped into the NGS battleground after the acquisition of an important supplier. Qiagen is now entering […]

April 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

Vibiosphen biotech infectious disease pierre fabre

News and Trends 15 Apr 2016

Pierre Fabre partners for Open Innovation in Infectious Disease

Pierre Fabre has a new partnership for its Open Innovation programme based on an extensive plant library. It will now count with VibioSphen to develop new phyto-chemicals to fight infectious diseases. Pierre Fabre is the 3rd largest Pharma in France, employing over 10,000 people and generating revenues of over €2Bn. Lately, this mid-sized company made efforts […]

April 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

evolva us navy composite material synbio

News and Trends 14 Apr 2016

European Biotech teams up with US Navy to engineer Military Materials

Evolva will join the US Navy to make new materials with its biosynthetic molecules – which could make it into aircrafts and ships. Evolva is a Synthetic biology Biotech headquartered near Basel (Switzerland), but with offices and R&D also in Denmark. It has developed its yeast platform to produce high-value chemicals via fermentation. So far, […]

April 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellnovo biotech diabetes medtech device horizon2020

News and Trends 13 Apr 2016

Mobile Pancreas to Change Life of Diabetics in New EU Programme

A new €4M European project brings a mobile insulin pump from France, computer models from Romania, and research from the UK & Spain together, in order to improve living with diabetes. Cellnovo, a MedTech split between France and the UK, was selected to participate in a new diabetes project funded by Horizon 2020, the EU grant […]

April 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT